CD274 and gastric cancer: Conclusions: These findings can provide stronger evidence to identify patients who truly benefit from first-line ICI immunotherapy based on PD-L1 expression in different segments and offer a basis for optimal treatment and research in advanced or metastatic GC or GEJC.